April 7 (Reuters) - German biotech company Evotec EVTG.DE is to receive around $100 million upfront following the closing of the sale of private Germany-based Tubulis to Gilead, the company said on Tuesday.
Gilead GILD.O said it would acquire Tubulis for up to $5 billion, as the U.S. drugmaker looks to boost its pipeline with a lucrative class of experimental cancer drugs.